Sanofi offers refunds for Cablivi in novel model for rebates
As risk sharing agreements slowly make their mark, Sanofi’s new Cablivi warranty program presents a newer take on existing methods.
Moderna takes aim at global expansion plans with manufacturing ramp-up
CMO Moves: Regulatory catalysts for therapy manufacturing -January
Collaboration with Janssen and Eli Lilly to address lack of paediatric medications
US FDA clears Transcenta’s IND for Rett syndrome treatment
BioCryst and Swixx BioPharma partner for commercialisation of Orladeyo
Analysis
View More
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
Themes
View MoreHealth Canada accepts Veru’s Covid-19 therapy NDS-CV for review
Proportion of deaths by day 60 was the primary endpoint of the double-blind, randomised, placebo controlled trial.
More themes
Insights
View MoreWho’s hiring who? Hiring activity related to robotics increased by 11% in the pharmaceutical industry in Q3 2022
The global pharmaceutical industry experienced an 11% rise in new job postings related to robotics in Q3 2022 compared with…
More Insights
Who’s hiring who? Hiring activity related to social responsibility increased by 10% in the pharmaceutical industry in Q3 2022
Who’s hiring who? Hiring activity related to artificial intelligence increased by 7% in the pharmaceutical industry in Q3 2022
Who’s hiring who? Hiring activity related to cloud decreased by 8% in the pharmaceutical industry in Q3 2022
Who’s hiring who? Hiring activity related to cybersecurity increased by 30% in the pharmaceutical industry in Q3 2022
Buyer's Guides
View More
Digital Magazine
View MorePharma Technology Focus
Pharma Technology Focus is our digital magazine, free to read online on all devices. Click the magazine cover to read the latest issue. You can subscribe for free to have each new issue delivered to your inbox.
South Korea authorises Novavax Covid-19 vaccine as booster dose
BioNTech to buy UK-based AI company InstaDeep
India’s Hetero receives WHO approval for Nirmacom to treat Covid-19
2022 in review: Regulation starts to catch up with AI in pharma